March 2024
1. CHEN YF, Liu NN, Wang JY, Sun JS, et al
   Use of 3D echocardiography facilitates analysis of thrombolytic efficacy in patients with persistent atrial fibrillation.
   J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001567.
   

   >> Share

   
   December 2023
2. RIVERA FB, Cha SW, Aparece JP, Jariyatamkitti S, et al
   Efficacy and safety of colchicine for the prevention of postoperative atrial fibrillation among patients undergoing major cardiothoracic surgery: a meta-analysis and meta-regression of randomized controlled trials.
   J Cardiovasc Pharmacol. 2023 Dec 28. doi: 10.1097/FJC.0000000000001533.
   

   >> Share

   
   
3. SPADAFORA L, Gaudio C, Biondi-Zoccai G, Frati G, et al
   Catalysts of cardiovascular electromechanical harmony? Unveiling the impact of RAS Inhibitors and ARNI on atrial fibrillation recurrence after ablation.
   J Cardiovasc Pharmacol. 2023 Dec 27. doi: 10.1097/FJC.0000000000001537.
   

   >> Share

   
   November 2023
4. SUN Q, Cui W, Zhang X, Tian Y, et al
   A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation.
   J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517.
   

   >> Share

   
   September 2023
5. AMARH E, Tisdale JE, Overholser BR
   Prolonged Exposure to Remdesivir Inhibits the Human Ether-A-Go-Go-Related Gene Potassium Current.
   J Cardiovasc Pharmacol. 2023;82:212-220.
   

   >> Share

   
   May 2023
6. AUGUSTIN N, Alvarez C, Kluger J
   The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
   J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439.
   

   >> Share

   
   March 2023
7. CATURANO A, Brunelli V, Spiezia S, Galiero R, et al
   Optimizing anticoagulation management in atrial fibrillation: beyond the guidelines. How and for whom?
   J Cardiovasc Pharmacol. 2023 Mar 30. doi: 10.1097/FJC.0000000000001423.
   

   >> Share

   
   February 2023
8. PAPAKONSTANTINOU PE, Tsioufis K
   Optimizing anticoagulation management in atrial fibrillation: beyond the guidelines. How and for whom?
   J Cardiovasc Pharmacol. 2023 Feb 14. doi: 10.1097/FJC.0000000000001405.
   

   >> Share

   
   November 2022
9. MOYSIDIS DV, Kartas A, Samaras A, Papazoglou AS, et al
   Prescription rates and prognostic implications of optimally-targeted guideline-directed medical treatment in heart failure and atrial fibrillation Insights from the MISOAC-AF trial.
   J Cardiovasc Pharmacol. 2022 Nov 22. doi: 10.1097/FJC.0000000000001390.
   

   >> Share

   
   
10. ALEXOPOULOS D, Dragona VM, Varlamos C, Ktenas D, et al
    One-year outcomes in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the Greek Antiplatelet Atrial Fibrillation (GRAPE-AF) registry.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001389.
    

    >> Share

    
    October 2022
11. BERNARDI M, Spadafora L, Biondi-Zoccai G
    Should we consider recombinant human brain natriuretic peptide to prevent post-operative atrial fibrillation?
    J Cardiovasc Pharmacol. 2022 Oct 10. pii: 00005344-990000000-00120.
    

    >> Share

    
    
12. PILOTE S, Simard C, Drolet B
    Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects.
    J Cardiovasc Pharmacol. 2022;80:616-622.
    

    >> Share

    
    
13. ESSA H, Dobson R, Lip GYH
    Chemotherapy-Induced Arrhythmias.
    J Cardiovasc Pharmacol. 2022;80:531-539.
    

    >> Share

    
    September 2022
14. MASTER YW, Master QZ, Master HC, Master ZW, et al
    Effects of recombinant human brain natriuretic peptide on atrial fibrillation after coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2022 Sep 9. pii: 00005344-990000000-00114.
    

    >> Share

    
    August 2022
15. GAO H, Li Y, Sun H, Huang X, et al
    Trough Concentration Deficiency of Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00103.
    

    >> Share

    
    
16. CATURANO A, Spiezia S, Brunelli V, Galiero R, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00109.
    

    >> Share

    
    
17. YAN J, Ai X
    Holiday Heart Syndrome, Atrial Fibrillation, and RyR2 antagonist.
    J Cardiovasc Pharmacol. 2022 Aug 10. pii: 00005344-990000000-00092.
    

    >> Share

    
    
18. GRECO LV, Migirov A, Ojamaa K, Li Y, et al
    Stabilizing Cardiac Ryanodine Receptor with Dantrolene Treatment Prevents Binge Alcohol Enhanced Atrial Fibrillation in Rats.
    J Cardiovasc Pharmacol. 2022 Aug 9. pii: 00005344-990000000-00090.
    

    >> Share

    
    
19. TUNCTAN B, Senol SP, Temiz-Resitoglu M, Yilmaz DE, et al
    Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
    J Cardiovasc Pharmacol. 2022;80:276-293.
    

    >> Share

    
    July 2022
20. TSAGKARIS C, Papazoglou AS, Kartas A, Samaras A, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Jul 29. pii: 00005344-990000000-00089.
    

    >> Share

    
    June 2022
21. HOSSEINI SH, Talasaz AH, Alidoosti M, Tajdini M, et al
    Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI).
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00067.
    

    >> Share

    
    
22. CHEN Y, Zhu M, Wang K, Xu Q, et al
    Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombus: An Updated Meta-Analysis of Cohort Studies and Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022;79:935-940.
    

    >> Share

    
    May 2022
23. CARNEVALE R, Biondi-Zoccai G, Giordano A, Pastori D, et al
    From the dining room to the atrium: can we modulate atrial fibrillation risk with micronutrients?
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00057.
    

    >> Share

    
    
24. OLIVERI F, Bongiorno A, Compagnoni S, Fasolino A, et al
    Statin and Post-Cardiac Surgery Atrial Fibrillation Prevention: Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 May 11. pii: 00005344-990000000-00049.
    

    >> Share

    
    
25. PETERSEN J, Castro L, Bengaard AKP, Pecha S, et al
    Muscarinic Receptor Activation Reduces Force and Arrhythmias in Human Atria Independent of IK,ACh.
    J Cardiovasc Pharmacol. 2022;79:678-686.
    

    >> Share

    
    April 2022
26. RUSSO V, Ammendola E, Gasperetti A, Bottino R, et al
    Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    J Cardiovasc Pharmacol. 2022;79:472-478.
    

    >> Share

    
    March 2022
27. HUANG J
    Circulating concentrations of nutrition-related factors are not causally associated with atrial fibrillation: a Mendelian randomization study.
    J Cardiovasc Pharmacol. 2022 Mar 25. pii: 00005344-990000000-00012.
    

    >> Share

    
    February 2022
28. LAM JC, Stevenson B, Lee YG, Maurer J, et al
    Intravenous to oral transition of amiodarone (IOTA): effect of various durations of overlap on atrial fibrillation recurrence post cardiothoracic surgery.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98047.
    

    >> Share

    
    January 2022
29. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    

    >> Share

    
    December 2021
30. WANG Z, Wang W, Li H, Zhang A, et al
    Ivabradine and Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98065.
    

    >> Share

    
    
31. LI W, Chen X, Xie X, Xu M, et al
    Comparison of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomised controlled trials.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98087.
    

    >> Share

    
    
32. WANG W, Liu J, Ye H, Wang M, et al
    Effect of Dexmedetomidine on Tachyarrhythmias after Cardiac Surgery: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98086.
    

    >> Share

    
    November 2021
33. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    

    >> Share

    
    
34. BURASHNIKOV A
    Atrial fibrillation induced by anticancer drugs and underling mechanisms.
    J Cardiovasc Pharmacol. 2021 Nov 17. pii: 00005344-900000000-98110.
    

    >> Share

    
    
35. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    

    >> Share

    
    October 2021
36. LO CT, Niu F, Fredriks DA, Hui RL, et al
    Evaluation of the effectiveness and safety of Direct Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation who are not Candidates for Warfarin in real world setting.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98121.
    

    >> Share

    
    August 2021
37. 
    Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience: Erratum.
    J Cardiovasc Pharmacol. 2021;78:330.
    

    >> Share

    
    
38. ZHANG M, Wang H, Bie M, Wang X, et al
    Caveolin-1 Deficiency Induces Atrial Fibrosis and Increases Susceptibility to Atrial Fibrillation by the STAT3 Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:175-183.
    

    >> Share

    
    July 2021
39. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
    Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
    J Cardiovasc Pharmacol. 2021;78:e55-e64.
    

    >> Share

    
    June 2021
40. CHARAFEDDINE K, Zakka P, Dargham BB, Abdulhai F, et al
    Potential Biomarkers in Atrial Fibrillation: Insight into their Clinical Significance.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98188.
    

    >> Share

    
    
41. SKORNOVA I, Samos M, Bolek T, Kamenistakova A, et al
    Direct oral anticoagulants plasma levels in atrial fibrillation patients at the time of bleeding: a pilot prospective study.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98186.
    

    >> Share

    
    
42. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    

    >> Share

    
    April 2021
43. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    

    >> Share

    
    March 2021
44. HEIDEMANN J, Tanislav C, Kostev K
    (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients with Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98230.
    

    >> Share

    
    
45. HORTIGON-VINAGRE MP, Zamora V, Burton FL, Smith GL, et al
    The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    J Cardiovasc Pharmacol. 2021;77:280-290.
    

    >> Share

    
    February 2021
46. ANOUASSI Z, Atallah B, Alsoud LO, El Nekidy W, et al
    Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region.
    J Cardiovasc Pharmacol. 2021;77:182-188.
    

    >> Share

    
    July 2020
47. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share